

PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen



Intyg  
Certificate

REC'D 26 JUL 1999

WIPO PCT

EP99/3509

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

*This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.*

(71) Sökande SBL Vaccin AB, Stockholm SE  
Applicant (s)

(21) Patentansökningsnummer 9801852-6  
Patent application number

(86) Ingivningsdatum 1998-05-26  
Date of filing

Stockholm, 1999-06-08

För Patent- och registreringsverket  
For the Patent- and Registration Office

*Emma Johnsson*

Emma Johnsson

Avgift  
Fee 170:-

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

29305/BN

**Method of producing *thy A*<sup>-</sup> strains of *Vibrio cholerae*, such strains and their use.**

5 The present invention relates to a method of producing *thy A*<sup>-</sup> strains of *Vibrio cholerae*, such strains and their use. The invention particularly relates to a strain of *Vibrio cholerae* that has been deprived of its *thy A* gene in the chromosome, i.e. a  $\Delta$  *thy A* strain. This strain may comprise one or several episomal  
10 autonomously replicating DNA elements, such as plasmids, having an optionally foreign, e.g. *E. coli*, functional *thy A* gene that enables the strain to grow in the absence of thymine in the growth medium, and optionally having a structural gene encoding a homologous or heterologous protein. The invention further relates to *thy A* nucleotide sequences and proteins encoded by them, and a  
15 vaccine comprising antigenic parts of a  $\Delta$  *thy A* strain and/or a *thy A*<sup>-</sup> strain of *V. cholerae* produced by the method of the invention.

**Background.**

20 The expression of recombinant genes in bacterial hosts is most often achieved by the introduction of episomal self-replicating elements (e.g. plasmids) that encode the structural gene of the protein of interest under the control of an appropriate promoter, into host bacteria. Such plasmids are most commonly maintained by the inclusion of selective marker genes that encode proteins that  
25 confer resistance to specific antibiotics (such as ampicillin, chloramphenicol, kanamycin, tetracycline etc.). They are then maintained in the host by addition of the appropriate antibiotic to the culture medium.

30 Stable maintenance of plasmids in host strains often requires the addition of the appropriate antibiotic selection without which they may segregate out giving rise to significant numbers of cells in any culture, that are devoid of plasmid and therefore cannot express the desired product.

However, the use of antibiotics in the production of recombinant proteins is undesirable for a number of reasons. Apart from the obvious increase in costs arising from the need to add them as a supplement to the growth medium, the use of antibiotics is considered a problem in the production of any recombinant protein intended for human or veterinary use. This is primarily for three reasons. Firstly, residual antibiotics can, in sensitive individuals, cause severe allergic reactions. Secondly, there is the possibility of selection for antibiotic resistant bacteria in the natural bacterial flora of those using the product, and finally, DNA encoding the antibiotic resistance may also be transferred to sensitive bacteria in individuals using the product, thereby also spreading undesired antibiotic resistance in a cohort.

There are already inventions dealing with this problem, one such is the *par* gene which will effectively kill all cells that do not retain a copy of the plasmid after each cell division [1].

Another patent application [2], which touches on the invention described herein, was based on the knowledge of the *thyA* DNA sequence in *E. coli*. The authors introduced the *thyA* gene on a plasmid but used host strains that were spontaneous *thyA*<sup>-</sup> mutants selected on the bases of trimethoprim resistance. Such mutants are not well defined (carrying point mutations or small deletions) and may revert to the wild-type (*i.e.* *thyA*<sup>+</sup>) at unacceptably high frequencies. This would lead to that the host bacteria could eliminate the plasmid and hence lose, or not give consistent and reliable, production of the desired recombinant product. An additional problem with trimethoprim selection is the possibility that resulting thymine dependence may arise due to a mutation in the dihydrofolate reductase (*folA*) gene and hence not be complemented by a plasmid-borne *thyA* gene [3]. This patent application has been discontinued at least in Europe.

The use of *V.cholerae* for expression of recombinant genes has been shown to be advantageous over other prokaryotic expression systems in common use in that specific recombinant products may be produced in large quantities and secreted into the culture medium, thereby facilitating downstream purification

procedures. This is in contrast to *E.coli* where the product often assembles in the periplasmic space [4]. One important factor endowing *V.cholerae* with this property is the *eps* genes in *V.cholerae* [5].

5 Thymidylate synthetase encoded by the *thyA* gene of *Escherichia coli* and other bacteria catalyses the methylation of deoxyuridylate (dUMP) to deoxythymidylate (dTMP) and is an essential enzyme in the biosynthesis of deoxyribothymidine triphosphate (dTTP) for incorporation into DNA. In the  
10 absence of this enzyme the bacteria become dependent upon an external source of thymine which is incorporated into dTTP by a salvage pathway encoded by the *deo* genes [6].  
Spontaneous mutants that are *thyA*<sup>-</sup> can be readily isolated on the basis of trimethoprim resistance. This antibiotic inhibits tetrahydrofolate regeneration from dihydrofolate produced by thymidylate synthetase-catalysed dTMP  
15 synthesis. Thus, if the cells are *thyA*<sup>-</sup> they become thymine dependent but no longer deplete the tetrahydrofolate pool in the presence of trimethoprim.

### Description of the invention

20 The present invention is, in its different aspects, based on the novel nucleotide sequence of the *thyA* gene in *Vibrio cholerae*. A useful application of the *thyA* gene is e.g. in maintenance of recombinant plasmids employed in the overproduction of recombinant proteins in *V. cholerae*, and in the use of the sequence for insertion of foreign genes in a selectable and site-specific manner  
25 into the *V. cholerae* chromosome .

One aspect of the invention is directed to a method of producing a *thyA*<sup>-</sup> strain of *Vibrio cholerae* comprising the step of site-directed mutagenesis in the *V. cholerae* chromosome for the deletion or insertion of gene nucleotides at the  
30 locus of  
the structural *thyA* gene having essentially the nucleotide sequence SEQ ID NO: 1 of FIG. 1,

and/or its 5'-flanking region having essentially the nucleotide sequence SEQ ID NO: 2 of FIG. 2,

and/or its 3'-flanking region having essentially the nucleotide sequence SEQ ID NO: 3 of FIG. 3.

5

The expression "having essentially the nucleotide sequence" in this specification and claims is intended to comprise nucleotide sequences which have some natural or unnatural nucleotide extensions, truncations, deletions or additions that do not interfere with the natural function of the nucleotide sequence in question.

10

Another aspect of the invention is directed to a *Vibrio cholerae* *thy A*<sup>-</sup> strain which is a  $\Delta$  *thy A* strain.

15

In an embodiment of this aspect of the invention the  $\Delta$  *thy A* strain of *V. cholerae* comprises one or several episomal autonomously replicating DNA elements having a functional *thy A* gene that enables the strain to grow in the absence of thymine in the growth medium.

20

In a preferred embodiment the episomal autonomously replicating DNA element is a plasmid.

25

In another preferred embodiment the  $\Delta$  *thy A* strain according to the invention comprises in an episomal autonomously replicating DNA element, especially a plasmid, a foreign *thy A* gene, such as an *E. coli* gene.

30

In a particularly preferred embodiment of this aspect of the invention the  $\Delta$  *thy A* strain according to the invention comprises in one or several episomal autonomously replicating DNA elements, especially a plasmids, in addition to a foreign *thy A* gene, such as an *E. coli* gene, also a structural gene encoding a homologous or heterologous protein, such as heat labile enterotoxin B-subunit of *Escherichia coli* (LTB) or *Schistosoma japonicum* glutathione S-transferase 26 kD protein (GST 26 kD).

A third aspect of the invention is directed to a nucleotide sequence of a structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 1 of FIG. 1.

5 A fourth aspect of the invention is directed to a nucleotide sequence of a 5'-flanking region of a structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 2 of FIG. 2.

10 A fifth aspect of the invention is directed to a nucleotide sequence of a 3'-flanking region of the structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 3 of FIG. 3.

15 The nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, are each useful for insertion of foreign genes in a selectable and site-specific manner into the *V. cholerae* chromosome, and for site-directed mutagenesis in the production of *Vibrio cholerae thy A<sup>-</sup>* strains.

20 A sixth aspect of the invention is directed to a protein encoded by a nucleotide sequence of a structural *thy A* gene of *Vibrio cholerae* according to the invention, such as a protein having the amino-acid sequence SEQ ID NO: 4 of FIG. 4.

25 An eighth aspect of the invention is directed to a protein encoded by a nucleotide sequence of a 5'-flanking region of a structural *thy A* gene of *Vibrio cholerae* according to the invention, such as the protein having the amino-acid sequence SEQ ID NO: 5 of FIG. 5.

The proteins according to the sixth and seventh aspect of the invention are each useful for research purposes, and potential targets for anti-microbial therapy.

30 A ninth aspect of the invention is directed to a vaccine comprising as immunising component(s) at least one antigenic component selected from antigenic parts of a *Vibrio cholerae*  $\Delta$  *thy A* strain according to the invention and a *thy A<sup>-</sup>* strain of

*Vibrio cholerae* produced by the method of the invention. The vaccine will be used for prophylactic and therapeutic treatment of cholera and optionally other infectious diseases, especially in cases where the used strain has been engineered to express foreign proteins. The vaccine will in addition to the immunising component(s) comprise a vehicle, such as physiological saline solution, and other components frequently used in vaccines such as buffers and adjuvants. Useful vehicles, buffers, adjuvants, and other components are disclosed in e.g. the European and US Pharmacopoeia.

#### Short description of the drawings

Figure 1 shows the nucleotide sequence SEQ ID NO:1 of the structural *thy A* gene of *Vibrio cholerae*.

Figure 2 shows the nucleotide sequence SEQ ID NO:2 of the 5'-flanking region of the structural *thy A* gene of *Vibrio cholerae*.

Figure 3 shows the nucleotide sequence SEQ ID NO:3 of the 3'-flanking region of the structural *thy A* gene of *Vibrio cholerae*.

Figure 4 shows the amino-acid sequence SEQ ID NO:4 of the protein encoded by the structural *thy A* gene of *Vibrio cholerae* (SEQ ID NO: 1).

Figure 5 shows the amino-acid sequence SEQ ID NO:5 of the protein encoded by the 5'-flanking region of the structural *thy A* gene of *Vibrio cholerae* (SEQ ID NO: 1).

Figure 6 shows the cloning of a *EcoRI/HindIII* fragment containing the *V.cholerae thyA* gene in pUC19.

Figure 7 shows a comparison of *thyA* gene products from *E. coli* [16], *V. cholerae* and *H. influenzae* [17] showing the high degree of homology between *V. cholerae* and *H. influenzae* compared with *E. coli*.

Figure 8 shows the insertion of a Kan<sup>R</sup>-resistance gene block in the *PstI* site of the *V.cholerae thyA* gene in pUC19.

Figure 9 shows PCR to generate a *thyA* -Kan fragment with *XbaI* ends.

Figure 10 shows ligation of the *thyA*-Kan fragment with *XbaI* ends in plasmid pNQ705.

**Figure 11** shows partial deletion of the *thyA* gene and the start of the Kan gene in pNEB193.

**Figure 12** shows *Xba*I cleavage to excise the  $\Delta thyA \Delta kan$  gene from pNEB193, ligation into *Xba*I restricted pDM4.

5 **Figure 13** shows an outline of a strategy to completely delete the *thyA* gene of *V. cholerae*.

**Figure 14** shows insertion of the 5' region upstream of *thyA* in pMT-SUICIDE 1; generation of pMT with 5 prim.

10 **Figure 15** shows insertion of the 3' region downstream of *thyA* in pMT with 5 prim; generation of pMT  $\Delta thyA$  *V. cholerae*.

**Figure 16** shows the expression vector pMT-eltB(*thyA*) used for expression of LTB in *V. cholerae* JS1569  $\Delta thyA$ .

**Figure 17** shows the expression vector pMT-GST(*thyA*) used for expression of GST in *V. cholerae* JS1569  $\Delta thyA$ .

15

## Description of experiments

### Strategy employed

20 In order to produce defined *thyA* mutants of *V. cholerae* that could be used as suitable production strains for recombinant proteins encoded on plasmids maintained by *thyA* complementation, it was first necessary to clone and characterise the wild-type gene and its 5' and 3' flanking regions. Our strategy was to first clone the *thyA* gene of *V. cholerae* on a plasmid, on the basis of  
25 complementation of the *thyA* auxotrophy in a strain of *E. coli* K12. Restriction analysis and subcloning experiments were done in order to locate the *thyA* structural gene on the large DNA fragment initially obtained. The appropriate region containing the *thyA* gene and its 5' and 3' flanking regions gene was then sequenced.

30

To verify that one of the sequenced genes was in fact the *thyA* gene of *V. cholerae*, homology comparisons were made with *thyA* sequences from other organisms. The cloned gene could also complement the *thyA* phenotype of a *V.*



*cholerae* mutant strain that had been selected on the basis of trimethoprim resistance. Sequence analysis of this mutant showed that it did indeed have a single base change in the gene we had identified as *thyA*, which resulted in a stop codon giving a non-functional truncated gene product.

5

Knowledge of the *thyA* sequence and that of the region surrounding it allowed the use of suitable suicide vectors for site-directed mutagenesis. Strategies considered were (a) insertional inactivation (b) a combination of insertional inactivation and gene deletion and (c) removal of the entire gene:

10

(a) Insertional inactivation of the *thyA* gene was achieved by insertion of a Kan<sup>R</sup> gene block (with the suicide vector pNQ705 [14]).

15

(b) A deletion of approximately 400 bp was made in the strain carrying the Kan<sup>R</sup> geneblock that removed 200 bp each from the *thyA* gene upstream of the insertion site and from the kanamycin resistance gene which was thereby inactivated. We thus obtained a deleted *thyA* gene where the deletion was in the central part of the gene and followed by an insertion of a non-coding region of DNA. This construct was inserted into the *V. cholerae* chromosome using the suicide vector pDM4 and resulted in a strain called JS1569  $\Delta$ *thyA*ΔKan.

20

(c) Complete removal of the *thyA* gene was done by ligating together the regions flanking the structural gene, taking care not to disrupt other open reading-frames (disruption of the adjacent *lgt* gene is also lethal). The DNA carrying the deletion was cloned into a novel suicide vector (PMT-SUICIDE-1) used for insertion of the sequence into the *V. cholerae* chromosome. The resulting strain is called JS1569  $\Delta$ *thyA*.

25

For expression of recombinant genes in these  $\Delta$ *thyA* strains of *V. cholerae*, two expression vectors were constructed. Each consisted of the *thyA* gene from *E. coli*, the origin of replication of the general purpose high copy-number vector pUC19, the *tac* promoter and the rho-independent *trpA* transcription terminator. In one of the two vectors the *lacI*<sup>q</sup> gene had been inserted in order to regulate expression from the *tac* promoter which also contained the *lac* operator sequence.

30

Two genes were cloned into these plasmids and expressed in the newly generated *thyA*-deleted strain of *V. cholerae*; JS1569 $\Delta$ *thyA*. The first encoded the B subunit of human heat-labile enterotoxin from *E. coli* (LTB) (Figure 16), the second was the sj26 glutathione-S-transferase (GST) from *Schistosoma japonicum* (Figure 17).

LTB is similar in structure to the B subunit of cholera toxin naturally produced by the host strain and was secreted into the growth medium. The other protein is eukaryotic in origin, coming from the Asian Liver Fluke. Sj26 GST is known to express to high levels in *E. coli* and accumulates in the cytoplasm. Expression of the two recombinant proteins was assessed on the basis of GM1 ELISA of the culture supernatant in the case of LTB and a commercially available assay in the case of GST. Both proteins were also analysed on the basis of SDS-PAGE and Western blots.

#### Origin of the *thyA* gene

The *thyA* gene was cloned from strain *V. cholerae* JS1569. This strain originates from the *V. cholerae* Inaba strain 569B of the classical biotype (ATCC No 25870). The strain has a deletion in the *ctxA* gene [7] and has been made rifampicin resistant [8].

#### Cloning of a 1.4 kB *HindIII*/*EcoRI* fragment encompassing the *V. cholerae thyA* gene.

Chromosomal DNA prepared by the CTAB method [9] was digested to completion with the restriction enzyme *HindIII*.

The digested DNA was ligated into the general purpose vector plasmid pBR322 (New England Biolabs Inc. Beverly, MA USA) which had been digested with *HindIII* and treated with alkaline phosphatase.

The ligation mixture was electroporated [10] into a *E. coli* HB101 strain that was phenotypically *ThyA*<sup>-</sup> (selected on the basis of trimethoprim resistance) and the culture spread onto modified Syncase (MS) agar plates [11] supplemented with 50  $\mu$ g/ml ampicillin, but containing no thymine. Thus transformants were

selected both on the basis of plasmid acquisition and the presence of a functional *thyA* gene.

Colonies that grew up were streaked out to single colonies on the same type of agar plates, and then grown up in MS broth supplemented with ampicillin.

5 Plasmid DNA was prepared by "Wizard minipreps" (ProMega Corp. Madison Wis.) and digested with *Hind*III. A fragment of approx. 10-12 kB was isolated, this clone was named ThyA B2.

10 To reduce the size of the fragment, the plasmid was cut with *Eco*RI and religated using T4 ligase. The ligated DNA was again electroporated into the *E.coli* strain described above using the same selective conditions for growth of transformants.

15 Colonies resulting from this experiment were isolated as described above and plasmid DNA purified and analysed by double digest with *Eco*RI and *Hind*III. A DNA fragment of approximately 1.4 kb remained which retained the ability to complement the *thyA* mutation in the *E. coli* host strain. This fragment was cloned into the plasmid pUC19 (New England Biolabs) that had been digested with the same two enzymes and treated with alkaline phosphatase. Following  
20 electroporation, transformants from the experiment were isolated and characterised as described above. This clone was called ThyA 1:2 (Figure 6).

**Verification that the 1.4 kB *Hind*III/*Eco*RI fragment contains the *thyA* gene.**

25 **Southern blot analysis.** To verify that the cloned fragment was indeed from *V.cholerae* chromosomal origin, DNA from strain JS1569 was digested to completion with *Hind*III and *Eco*RI and *Hind*III. The DNA fragments were resolved by agarose electrophoresis together with *Hind*III digested clone ThyA B2 and *Eco*RI and *Hind*III digested clone ThyA 1:2.

30 After electrophoresis the DNA was transferred to a Nylonmembrane, immobilized by UV irradiation and hybridised (under stringent conditions) with the 1.5 kB fragment excised from clone ThyA 1:2 that had been labelled with <sup>32</sup>P dCTP using Amershams Multiprime kit.

**Results.** In both *Hind*III digested chromosomal DNA and in *Hind*III digested clone ThyA B2 an approx. 10 kB band was evident. Likewise in *Eco*RI/*Hind*III digested chromosomal DNA and clone ThyA 1:2 plasmid DNA a 1.4 kB band was evident (data not shown). These data demonstrated that the cloned fragment was derived from *V.cholerae* JS1569 DNA.

**Transformation of JS1569 ThyA<sup>-</sup> with the plasmid ThyA 1:2.** To verify that the 1.4 B cloned *Eco*RI/*Hind*III fragment could support growth of phenotypically ThyA<sup>-</sup> *V.cholerae*, a thymine dependent mutant of JS1569 (*V.cholerae* JS1569 4.4) was electroporated with the plasmid ThyA 1:2. Electroporation and selective media were as described above. JS1569 4.4 does not grow on MS medium without the addition of thymine.

**Results.** Colonies of JS1569 4.4 were isolated that grew in the absence of thymine. All were shown to harbour the ThyA 1:2 plasmid, thus supporting the assumption that the cloned fragment contained the *thyA* gene from *V.cholerae*.

**DNA sequencing of the plasmid ThyA 1:2.** Plasmid DNA was sequenced by the dideoxy chain termination method [12] using the ABI PRISM™ Dye terminator cycle sequencing kit (Perkin Elmer). Both commercially available as well as custom made primers were used. The DNA sequences were analysed on an ABI PRISM 373 automatic sequencer (Perkin Elmer). Data were analysed using the AutoAssembler Software package (Perkin Elmer). Homology searches with the found DNA sequence were done with the GCG program [13].

**Results.** The best homologies were with thymidylate synthetases from various species. Note that the homology with *E.coli* thymidylate synthetase is rather weak. (Figure 7)

## Strategy for deletion of the *thyA* gene in *V.cholerae* JS1569.

Two different strategies were used for obtaining defined *thyA* mutants of *V. cholerae* JS1569, the first involved inactivation of the *thyA* gene by insertion of a Kan<sup>R</sup> gene block followed by partial deletion of the *thyA* gene and the Kan<sup>R</sup> gene block.

The second strategy was directed to completely delete the *thyA* gene from the chromosome by means of a novel suicide vector pMT SUICIDE-1. This vector contains the 5' and 3' flanking regions of the *thyA* gene as well as the R6K origin of replication and the RP4 *mob* genes.

To replace the *thyA* gene of strain JS1569 we decided to use the already thymine-dependent JS1569 4.4 since preliminary experiments indicated that there is a strong selective disadvantage to go from wildtype to thymine dependence even in the presence of high levels of exogenous thymine.

15

### Inactivation of the *thyA* gene by insertion of a Kan<sup>R</sup> gene block

Our strategy involved inactivation of the *thyA* gene by insertion of a kanamycin resistance gene into a unique *Pst*I site in the *thyA* gene in the form of a Kan<sup>R</sup> gene block (Pharmacia) (Figure 8). This construct was amplified by PCR (Expand<sup>TM</sup>High Fidelity PCR system Boehringer Mannheim) with primers that incorporate *Xba*I ends so that it could be transferred into the suicide plasmid pNQ705 [14] which carries a unique *Xba*I site and the chloramphenicol resistance gene.

20

The following primers were used for PCR amplification of the insertionally inactivated gene:

25

30

ThyA-10: 5' **GCT CTA GAG CCT TAG AAG GCG TGG TTC** 3'

corresponding to bases 557 to 575 in SEQ ID NO: 2 (Figure 2) with an added *Xba*I site (in bold)

and

ThyA-11: 5' **GCT CTA GAG CTA CGG TCT TGA TTT ACG GTA T** 3'

corresponding to the complementary sequence of bases 235 to 257 in SEQ ID NO:2 (Figure 3) with an added *Xba*I site (in bold) (Figure 9 + 10).

The resulting plasmid was then transferred to the *E.coli* S-17 that was used in conjugation experiments.

Since the recipient strain JS1569 4.4 is rifampicin resistant and chloramphenicol sensitive and the donor strain *E.coli* S-17 is both chloramphenicol and kanamycin resistant, transconjugants were selected by selection for resistance to both rifampicin and kanamycin.

The resulting *V. cholerae* strains however would also be chloramphenicol resistant since the entire plasmid would initially be inserted into the chromosome.

Exconjugants that had incorporated the inactivated *thyA* gene carrying the Kan<sup>R</sup> geneblock into the chromosome and lost the pNQ705 plasmid could then be selected among those that were chloramphenicol sensitive but remained kanamycin resistant.

To verify insertion of the Kanamycin resistance gene in the *thyA* gene the entire *thyA* gene was PCR amplified with primers *thyA*-10 and *thyA*-11, and the size of the resulting fragment compared to that of the native *thyA* gene. The expected *thyA* fragment of 2.6 kb compared to that of the native *thyA* gene of 1.4 kb was found.

**Results.** Exconjugants were shown to be kanamycin resistant, chloramphenicol sensitive and when amplified by PCR, shown to have incorporated the kanamycin resistance gene block into the chromosome. Sequencing of the amplified fragment showed that the only defect in the gene was due to the insertion of the kanamycin gene. This indicated that the recombination event that had incorporated the insertionally inactivated gene into the chromosome had also eliminated the point mutation that had made the recipient strain (JS1569 4.4) thymine dependent. Growth of the resulting strain was only observed if the growth medium was supplemented with thymine (200 µg/ml).

### Partial deletion of the *thyA* gene and the Kan<sup>R</sup> gene block

To further ensure a nonreversible *thyA* mutation the insertionally inactivated *thyA* was subcloned as a *Xba*I fragment into pNEB 193 (New England Biolabs).

PCR primers were designed that deleted 209 basepairs from the *thyA* gene and removed 261 basepairs from the Kan<sup>R</sup> geneblock.

Thus the *thyA* gene was further disrupted and that the kanamycin resistance gene was also inactivated (by removal of the start of the coding region). The overall result of this procedure was a strain carrying a deleted *thyA* gene that also contained an insertion of noncoding DNA.

ThyA-14: 5' GGG GGC **TCG AGG** GGC ACA TCA CAT GAA<sup>3'</sup>  
ThyA-15: 5' CCC CCC **TCG AGC** GCC AGA GTT GTT TCT GAA<sup>3'</sup>

Letters in **bold** indicate *Xho*I cleavage sites (Figure 11).

After PCR amplification a DNA fragment was obtained encompassing the entire plasmid with exception of the deleted region. The amplified DNA was digested with *Xho*I, self ligated and transformed into *E.coli* HB101. Colonies were selected for on plates containing ampicillin. Individual colonies were selected and restreaked. Small-scale plasmid preparations from individual colonies yielded the expected restriction patterns when analysed with *Xba*I, *Xho*I, *Hind*III and *Rsa*I restriction enzymes.

The incomplete *thyA* gene carrying an inactivated kanamycin resistance gene was cut out from the vector by *Xba*I digestion, purified and ligated into pDM4 [15] (Figure 12). PDM4 is a suicide vector derived from pNQ705 containing the *SacBR* gene from *Bacillus subtilis* and a modified multicloning site.

After transfer of the pDM4 ( $\Delta$ *thyA* $\Delta$ Kan) plasmid to the *E.coli* S-17 strain a transconjugation experiment was performed. This time the *V.cholerae* JS1569 *thyAKan* strain obtained above was used as recipient strain. The mating was done as described above with selection for rifampicin and chloramphenicol. After growth in this medium colonies were selected on medium containing 10% sucrose in the absence of chloramphenicol. Sucrose induces the *sacBR* gene which encodes levansucrase that converts sucrose to levan. This compound is toxic to many Gram negative organisms. In this way

clones still carrying the suicide plasmid were killed leaving exconjugants that had lost the plasmid.

**Results.** A colony was selected that was chloramphenicol and kanamycin sensitive. PCR amplification of the *thyA* region with the primers ThyA-10 and thyA-11 confirmed that the *thyA*Kan fragment (2.6 kb) on the chromosome had been replaced with the  $\Delta$ *thyA* $\Delta$ Kan fragment (2.1 kb).

Growth of the resulting strain was only observed if the growth medium was supplemented with thymine (200  $\mu$ g/ml). This strain was named *V.cholerae* JS1569  $\Delta$ *thyA* $\Delta$ Kan.

#### Direct deletion of the *thyA* gene in *V. cholerae*.

For this approach the 5' and 3' sequences flanking the *thyA* gene were used. A novel suicide vector was constructed, pMT SUICIDE-1 (Fig 14) that contains the R6K origin of replication, the *mob* genes from RP4, a chloramphenicol resistance gene and a multicloning site from Litmus 28 (New England Biolabs). Effectively, a modified fragment was constructed in which the *thyA* coding region was replaced by a multicloning site (derived from Litmus 28) leaving only the 5' and 3' region of the *thyA* locus from *V.cholerae*. The resulting plasmid was used to generate a *V. cholerae* strain in which the entire *thyA* gene had been deleted.

As starting material for this construction the pMT SUICIDE-1 plasmid was used (M. Lebens, unpublished).

From the 5' and 3' regions of the *thyA* locus the following PCR primers were designed:

ThyA-33: <sup>5'</sup>**GGA CTA GTG GGT TTC CTT TTT GCT AT**<sup>3'</sup>  
corresponding to bases 109 to 126 in the SEQ ID NO:2 (figure 2) (5' region of the *thyA* region) with a *SpeI* site (indicated in bold) and



ThyA-34: 5'CCC CGC **TCG AGA** CCC TAT TTT GCT GCT AC<sup>3'</sup>  
corresponding to the complementary sequence of base 815 to 832 in the SEQ  
ID NO:2 with a *Xho*I site (indicated in bold) attached to it.

This primer pair gives a PCR fragment of 743 bases corresponding to the 5'  
flanking region of the *thyA* gene.

ThyA-31: 5'CGG **GGT ACC** TGG CTT GAT GGG TTT TAT<sup>3'</sup>

corresponding to bases 22 to 39 in the SEQ ID NO:3 (figure 3) (3' region of the  
*thyA* region)  
with a *Kpn*I site (indicated in bold) and

ThyA-32: 5'GAA **GGC CTT** CGC CTC TGC TTG CGA CT<sup>3'</sup>

corresponding to the complementary sequence of bases 731 to 749 in the SEQ  
ID NO:3 with a *Stu*I site (indicated in bold).  
This primer pair gives a PCR fragment of 746 bases corresponding to the 3'  
flanking region of the *thyA* gene..

As template for the PCR reactions a chromosomal DNA preparation from *V.*  
*cholerae* JS1569 was used (Figure 13).

The amplified DNA were digested with the appropriate restriction enzymes and  
cloned into the pMT-SUICIDE 1 vector (Figure 14 and 15) yielding the plasmid  
pMTΔ*thyA* *V.cholerae* that contains approximately 700 base-pairs of the 5'  
region upstreams of the *thyA* gene and the same number of base-pairs of the 3'  
region downstreams of the *thyA* gene.

This plasmid was transferred to *E.coli* S17-1 and used in conjugation  
experiments as described above. As recipient the *V. cholerae* JS1569 4.4 strain

was used. Matings were done on LB agar supplemented with rifampicin, chloramphenicol and thymine. Exconjugants that had lost the suicide plasmid from the chromosome were selected on the basis of chloramphenicol sensitivity.

5 **Results.** A chloramphenicol sensitive and rifampicin resistant colony was selected. PCR amplification with the primers ThyA-10 and ThyA-11 of the *thyA* region resulted in a 1.4 kb fragment from the native *thyA* gene and a 0.6 kb fragment from the  $\Delta$ *thyA* gene. This confirmed that the *thyA* structural gene on the chromosome had been deleted. Furthermore the bacteria could only grow in  
10 medium complemented with thymine. This strain is named *V. cholerae* JS1569  $\Delta$ *thyA*.

**Expression of the B subunit of heat-labile enterotoxin from *E. coli* (LTB) and the sj26 glutathione-S-transferase (GST) from *Schistosoma japonicum***  
15 **in *V. cholerae* JS1569  $\Delta$ *thyA*.**

Two expression vectors were constructed, each consisted of the *thyA* gene from *E. coli*, the origin of replication of the high copy-number vector pUC19, the *tac* promoter and the rho-independent *trpA* transcription terminator. In one of the  
20 two vectors the *lacI*<sup>q</sup> gene had been inserted in order to regulate expression from the *tac* promoter which also contained the *lac* operator sequence (figure 16 and 17).

**Expression of the LTB protein in *V.cholerae* JS1569  $\Delta$ *thyA* strain.**

25 The expression vector shown in figure 16 was electroporated into *V.cholerae* JS1569  $\Delta$ *thyA*. Transformants were selected for on MS -agar. Individual colonies were grown up to produce mini-plasmid preps that were checked by restriction enzyme analysis. For expression a transformant was grown in MS medium at 37°C in a shaker culture. The culture medium was harvested and  
30 assayed for LTB by the GM1- ELISA.

**Results.** The culture was found to produce approximately 300 µg/ml of LTB as assayed by the GM1 ELISA. SDS-PAGE and Western blot using an LTB specific monoclonal antibody further verified that the secreted protein was LTB.

5 **Expression of the GST protein in *V.cholerae* JS1569  $\Delta$ thyA strain**

The sj26 glutathione-S-transferase (GST) from *Schistosoma japonicum* was cloned in the expression vector shown in figure 17. This vector is identical to the first except for the sequence of the *lacI<sup>q</sup>* gene. The *lacI<sup>q</sup>* allows for controlled expression of recombinant proteins. The vector was electroporated into  
10 *V.cholerae* JS1569  $\Delta$ thyA . Transformants were selected for on MS -agar. Individual colonies were grown up to produce mini-plasmid preps that were checked by restriction enzyme analysis. For expression a transformant was grown in MS medium at 37°C in a shaker culture with addition of IPTG.

15 **Results.** The recombinant protein was found in the cytoplasm of the *V. cholerae* bacteria. SDS-PAGE and Western blot with a GST specific monoclonal antibody (Pharmacia BioTech, Uppsala) confirmed that GST was expressed. The level of GST expression was more difficult to determine than for LTB since the protein was expressed intracellularly but was judged to be in the same range as for LTB.

# References

=NO 84/21172

1. Molin, S., K. A. Gerdes. 1984. Stabilized plasmids. US Patent 4,760,022.
2. Morona, R., and S. R. Attridge. 1987. Non-antibiotic marker system. EPC-A-0251579.
3. Green, J. M., B. P. Nichols, and R. G. Matthews. 1996. Folate biosynthesis, reduction and polyglutamylation. *In*: F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter and H. E. Umbarger (Eds.) *Escherichia coli* and *Salmonella* cellular and molecular biology. ASM Press Washington D.C. pp665-673.
4. Neill, R. J., B. E. Ivins, and R. K. Holmes. 1983. Synthesis and secretion of the plasmid-coded heat-labile enterotoxin of *Escherichia coli* in *Vibrio cholerae*. *Science*. **221**: 289-290.
5. Sandkvist, M., M. Bagdasarian, S. P. Howard, and V. J. DiRita. 1995. Interaction between the autokinase EpsE and EpsL in the cytoplasmic membrane is required for extracellular secretion in *Vibrio cholerae*. *EMBO J*. **14**:1664-1673.
6. Neuhard, J. and R. A. Kelln. 1996. Biosynthesis and conversions of pyrimidines. *In*: F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter and H. E. Umbarger (Eds.) *Escherichia coli* and *Salmonella* cellular and molecular biology. ASM Press Washington D.C. pp580-599.
7. Kaper, J. B., H. Lockman, M. M. Baldini, and M. M. Levine. 1984. A recombinant live oral cholera vaccine. *Biotechnology* **2**:345-349.
8. Sanchez, J., and J. Holmgren. 1989. Recombinant system for overexpression of cholera toxin B subunit in *Vibrio cholerae* as a basis for vaccine development. *Proc. Natl. Acad. Sci. USA*. **86**:481-485.

9. Wilson, K. 1994. Preparation of genomic DNA from Bacteria. *In* Current protocols in Molecular Biology (F.A. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J. G. Seidman, J.A. Smith, and K. Struhl, eds.) pp. 2.4.1-2.4.2 John Wiley & Sons, New York.  
5
10. Sheen, J. 1994. High-efficiency transformation by electroporation. *In* Current protocols in Molecular Biology (F.A. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J. G. Seidman, J.A. Smith, and K. Struhl, eds.) pp. 1.8.4-1.8.5. John Wiley & Sons, New York.  
10
11. Lebens, M., S. Johansson., J. Osek., M. Lindblad and J. Holmgren. 1993. Large-scale production of *Vibrio cholerae* toxin B subunits for use in oral vaccines. *Biotechnology*. 11:1574-1578.  
15
12. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 74:5463-5467.  
20
13. Program Manual for the Wisconsin Package. Version 8. September 1994. Genetics Computer Group, 575 Science Drive, Madison Wisconsin.  
25
14. Milton, D. L., A. Nordqvist, and H. Wolf-Watz. 1992. Cloning a metalloprotease gene involved in the virulence mechanism of *Vibrio anguillarum* *J. Bacteriol.* 174:7235-7244.  
30
15. Milton, D. L., R. O'Toole, P. Högstädt, and H. Wolf-Watz. 1996. Flagellin A is essential for the virulence of *Vibrio anguillarum* *J. Bacteriol.* 176:1310-1319.
16. Belfort, M., G. Maley, J. Pedersen-Lane and F. Maley. 1983. Primary tructure of the *Escherichia coli thyA* gene and its thymidylate synthase product. *Proc. Natl. Acad. Sci. USA* 80: 4914-4918.

17. Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F., Kerlavage, A. R., Bult, C. J., Tomb, J.-F., Dougherty, B. A., Merrick, J. M., McKenney, K., Sutton, G., FitzHugh, W., Fields, C. A., Gocayne, J. D., Scott, J. D., Shirely, R., Liu, L.-I., Glodek, A., Kelley, J. M., Weidman, J. F.,  
5 Phillips, C. A., Spriggs, T., Hedblom, E., Cotton, M. D., Utterback, T. R., Hanna, M. C., Nguyen, D. T., Saudek, D. M., Brandon, R. C., Fine, L. D., Fritchman, J. L., Fuhrmann, J. L., Geoghagen N. S. M., Gnehm, C. L., McDonald, L. A., Small, K. V., Fraser, C. M., Smith, H. O., and J. C. Venter. 1995. Whole-genome random sequencing and assembly of *Haemophilus influenzae* RD. *Science*  
10 **269**:496-512.

M 12.07.99

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: SBL VACCIN AB
- (B) STREET: LUNDAGATAN 2
- (C) CITY: SOLNA
- (E) COUNTRY: SWEDEN
- (F) POSTAL CODE (ZIP): 105 21

(ii) TITLE OF INVENTION: Vibrio cholerae strains and their use.

(iii) NUMBER OF SEQUENCES: 5

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 849 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vibrio cholerae

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTGAAACAGT ATTTAGATCT TTGTCAGCGC ATCGTCGATC AAGGTGTTTG GGTGAAAAT	60
GAACGAACGG GCAAGCGTTG TTTGACTGTG ATTAATGCCG ATTTGACCTA CGATGTGGGC	120
AACAATCAGT TTCCTCTAGT GACTACACGC AAGAGTTTTT GGAAAGCTGC CGTAGCCGAG	180
TTGCTCGGCT ATATTCGTGG TTACGATAAT GCGGCGGATT TTCGCCAATT AGGTACCAAA	240
ACCTGGGATG CTAATGCCAA TTAAACCAA GCATGGCTCA ACAATCCTTA CCGTAAAGGT	300
GAGGATGACA TGGGACGCGT GTATGGTGTT CAGGGTAGAG CTTGGGCTAA GCCTGATGGT	360
GGTCATATTG ACCAGTTGAA AAAGATTGTT GATGATTGA GCCGTGGCGT TGATGACCGA	420

```

GGTGAAATTC TTAACCTTCTA CAATCCGGGT GAATTCACAC TGGGGTGTTT GCGCCCTTGC      480
ATGTACAGCC ATCATTTTTTC ATTGCTGGGG GATACCTTGT ATCTCAACAG TACTCAGCGT      540
TCATGTGATG TGCCCTTGGG GTTGAATTC AACATGGTGC AGGTTTATGT GTTCCTTGCG      600
CTGATGGCAC AGATCACAGG GAAAAAGCCG GGCTTGGCGT ATCACAAGAT CGTCAATGCG      660
CACATTTACC AAGATCAACT CGAATTGATG CGCGATGTGC AGCTAAAACG TGAGCCATTC      720
CCAGCGCCTC AGTTCCATAT CAATCCAAAG ATTAAAACAC TGCAGGATTT GGAAACTTGG      780
GTCACCTTGG ATGATTTTGA CGTCACCGGA TATCAGTTCC ACGATCCTAT TCAATACCCG      840
TTTTCAGTC      849

```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 838 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: VIBRIO CHOLERA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```

GAGAAGGTTT GTTATGCCTC AGGGTTATCT GCAGTTTCCC AATATTGACC CCGTATTGTT      60
TTCGATCGGC CCTCTAGCGG TCGCTGGTA TGGCTTGATG TATTGGTGG GTTTCCTTTT      120
TGCTATGTGG TTGGCCAATC GCCGAGCGGA TCGCGCGGGC AGTGGTTGGA CGCGTGAGCA      180
AGTCTCTGAC TTGTTATTCG CCGGCTTTTT AGGTGTAGTG ATCGGTGGCC GAGTTGGTTA      240
TGTGATCTTC TACAATTTTG ATCTGTTCTT TGCTGACCCT CTTTATTTAT TCAAAGTGTG      300
GACTGGCGGC ATGTCCTTCC ACGGCGGCTT ATTGGGTGTG ATCACCGCCA TGTTCTGGTA      360
TGCGCGTAAA AACCAACGCA CTTTCTTTGG TGTGGCCGAT TTTGTTGCCC CTTTAGTGCC      420
ATTCGGTTTG GGGATGGGAC GTATCGGTAA CTTTATGAAT AGTGAACTTT GGGGACGAGT      480
AACGGATGTG CTTGGGCTT TTGTATTCCC TAATGGTGGC CCACTGCCGC GCCATCCTTC      540

```



M 10799

ACAGCTTTAT GAATTCGCCT TAGAAGGCGT GGTTCGTTC TTTATTCTTA ATTGGTTTAT	600
TGGTAAACCT CGTCCGCTAG GCAGCGTATC CGGACTGTTT TTAGCTGGAT ACGGTACATT	660
CCGCTTCCTT GTGGAATACG TCCGTGAGCC AGATGCTCAG TTGGGTCTGT TTGGTGGCTT	720
CATTTCAATG GGGCAAATCC TCTCCTTACC TATGGTGATC ATCGGTATTT TGATGATGGT	780
TTGGTCTTAC AAGCGCGGTT TGTATCAAGA CCGTGTAGCA GCAAAATAGG GTAGTTAG	838

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1222 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Vibrio cholerae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TAATCCCGTA TTCAGGCGGT ATGGCTTGAT GGGTTTTATA TAAAAAAGC TCCCGAAGGT	60
CGGGAGCTTT TTTTATACAG ATGATGCTTT AACGCTTAAG CGGTTAGGGC AAGAATGCTG	120
CCGGGGATGA CGACAAACAC ACCCAATAAG TAACTACCA CCACCATTTT GCTCTTACAA	180
GCCCAAGTTG AGATGAGCTC AGCACCTTTA ATAGGCAGTT CGCGTAAGAA AGGAATACCG	240
TAAATCAAGA CCGTAGCCAT CAAGTTAAAG CTTAAGTGCA CCAGCGCAAT TTGCAGAGCA	300
AACACGGCAA ACTCACCAGA GACAGCGGTT GCGGCGAGCA GAGCAGTAAT ACAAGTGCCA	360
ATGTTCGCAC CTAAGGTAAA TGGGTAGATT TCACGCACTT TCAGCACGCC AGAGCCCACG	420
AGAGGAACCA TTAGGCTGGT TGTGGTCGAT GAAGATTGAA CTAATACCGT AACCACTGTA	480
CCTGAAGCAA TACCGTGTAG TGGGCCTCGG CCAATCGCAT TTTGTAGAAT TTCACGTGCG	540
CGGCCAACCA TCAAACCTCTT CATCAGTTTG CCCATCACCG TAATGGCGAC GAAAATGGTC	600
GCAATACCCA ATACGATAAG TGCACACCA CCGAAAGTAT TACCAATAC CGAAAGCTGG	660
GTTTCAAGCC CTGTGATGAC AGGTTTGGTA ATCGGTTTGA TAAATCAAA ACCTTTCATG	720
CTCATATCGC CAGTCGCAAG CAGAGGCGAA ACGAGCCAGT GTGAGACTTT CTCTAAAATG	780

M 12.07.99

```

CCAAACATCA TTTCTAGAGG TAGGAAGATC AGCACCGCGA GAAGATTGAA AAAATCGTGG      840
ATGGTGGCAC TGGCGAAAGC ACGGCGAAAC TCTTCTTTAC AGCGCATATG GCCAAGGCTG      900
ACGAGAGTAT TGGTCACAGT AGTACCAATA TTGGCACCCA TCACCATAGG AATCGCGGTT      960
TCAACCGGTA ACCCACC GGC AACGAGACCA ACAATAATAG AAGTCACCGT GCTTGAGGAT     1020
TGAATCAGTG CCGTTGCCAC TAAACCAATC ATCAATCCTG CAATTGGGTG GGAAGCAAAT     1080
TCAAATAGAA CTTTGGCTTG ATCGCCGGTT GCCCATTAA AACCGCTGCC GACCATCGCG      1140
ACTGCAAGAA GTAGTAAATA CAGCATGAAA GCCAAGTTTG CCCAACGTAG GCCTTTCGTG      1200
GTCAGCGAAA TCGGCGCTGC AG                                              1222

```

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 283 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Vibrio cholerae*

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Val Lys Gln Tyr Leu Asp Leu Cys Gln Arg Ile Val Asp Gln Gly Val
1           5           10           15
Trp Val Glu Asn Glu Arg Thr Gly Lys Arg Cys Leu Thr Val Ile Asn
20          25          30
Ala Asp Leu Thr Tyr Asp Val Gly Asn Asn Gln Phe Pro Leu Val Thr
35          40          45
Thr Arg Lys Ser Phe Trp Lys Ala Ala Val Ala Glu Leu Leu Gly Tyr
50          55          60
Ile Arg Gly Tyr Asp Asn Ala Ala Asp Phe Arg Gln Leu Gly Thr Lys
65          70          75          80
Thr Trp Asp Ala Asn Ala Asn Leu Asn Gln Ala Trp Leu Asn Asn Pro
85          90          95
Tyr Arg Lys Gly Glu Asp Asp Met Gly Arg Val Tyr Gly Val Gln Gly
100         105         110

```

Arg Ala Trp Ala Lys Pro Asp Gly Gly His Ile Asp Gln Leu Lys Lys  
 115 120 125  
 Ile Val Asp Asp Leu Ser Arg Gly Val Asp Asp Arg Gly Glu Ile Leu  
 130 135 140  
 Asn Phe Tyr Asn Pro Gly Glu Phe His Met Gly Cys Leu Arg Pro Cys  
 145 150 155 160  
 Met Tyr Ser His His Phe Ser Leu Leu Gly Asp Thr Leu Tyr Leu Asn  
 165 170 175  
 Ser Thr Gln Arg Ser Cys Asp Val Pro Leu Gly Leu Asn Phe Asn Met  
 180 185 190  
 Val Gln Val Tyr Val Phe Leu Ala Leu Met Ala Gln Ile Thr Gly Lys  
 195 200 205  
 Lys Pro Gly Leu Ala Tyr His Lys Ile Val Asn Ala His Ile Tyr Gln  
 210 215 220  
 Asp Gln Leu Glu Leu Met Arg Asp Val Gln Leu Lys Arg Glu Pro Phe  
 225 230 235 240  
 Pro Ala Pro Gln Phe His Ile Asn Pro Lys Ile Lys Thr Leu Gln Asp  
 245 250 255  
 Leu Glu Thr Trp Val Thr Leu Asp Asp Phe Asp Val Thr Gly Tyr Gln  
 260 265 270  
 Phe His Asp Pro Ile Gln Tyr Pro Phe Ser Val  
 275 280

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 271 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Vibrio cholerae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Pro Gln Gly Tyr Leu Gln Phe Pro Asn Ile Asp Pro Val Leu Phe  
 1 5 10 15  
 Ser Ile Gly Pro Leu Ala Val Arg Trp Tyr Gly Leu Met Tyr Leu Val  
 20 25 30

Gly Phe Leu Phe Ala Met Trp Leu Ala Asn Arg Arg Ala Asp Arg Ala  
 35 40 45  
 Gly Ser Gly Trp Thr Arg Glu Gln Val Ser Asp Leu Leu Phe Ala Gly  
 50 55 60  
 Phe Leu Gly Val Val Ile Gly Gly Arg Val Gly Tyr Val Ile Phe Tyr  
 65 70 75 80  
 Asn Phe Asp Leu Phe Leu Ala Asp Pro Leu Tyr Leu Phe Lys Val Trp  
 85 90 95  
 Thr Gly Gly Met Ser Phe His Gly Gly Leu Leu Gly Val Ile Thr Ala  
 100 105 110  
 Met Phe Trp Tyr Ala Arg Lys Asn Gln Arg Thr Phe Phe Gly Val Ala  
 115 120 125  
 Asp Phe Val Ala Pro Leu Val Pro Phe Gly Leu Gly Met Gly Arg Ile  
 130 135 140  
 Gly Asn Phe Met Asn Ser Glu Leu Trp Gly Arg Val Thr Asp Val Pro  
 145 150 155 160  
 Trp Ala Phe Val Phe Pro Asn Gly Gly Pro Leu Pro Arg His Pro Ser  
 165 170 175  
 Gln Leu Tyr Glu Phe Ala Leu Glu Gly Val Val Leu Phe Phe Ile Leu  
 180 185 190  
 Asn Trp Phe Ile Gly Lys Pro Arg Pro Leu Gly Ser Val Ser Gly Leu  
 195 200 205  
 Phe Leu Ala Gly Tyr Gly Thr Phe Arg Phe Leu Val Glu Tyr Val Arg  
 210 215 220  
 Glu Pro Asp Ala Gln Leu Gly Leu Phe Gly Gly Phe Ile Ser Met Gly  
 225 230 235 240  
 Gln Ile Leu Ser Leu Pro Met Val Ile Ile Gly Ile Leu Met Met Val  
 245 250 255  
 Trp Ser Tyr Lys Arg Gly Leu Tyr Gln Asp Arg Val Ala Ala Lys  
 260 265 270

29305/BN

# CLAIMS

- 5 1. A method of producing a *thy A*<sup>-</sup> strain of *Vibrio cholerae* comprising the step of site-directed mutagenesis in the *V. cholerae* chromosome for the deletion or insertion of gene nucleotides at the locus of the structural *thy A* gene having essentially the nucleotide sequence SEQ ID NO: 1 of FIG. 1,  
10 and/or its 5'-flanking region having essentially the nucleotide sequence SEQ ID NO: 2 of FIG. 2,  
and/or its 3'-flanking region having essentially the nucleotide sequence SEQ ID NO: 3 of FIG. 3.
- 15 2. A *Vibrio cholerae thy A*<sup>-</sup> strain which is a  $\Delta$  *thy A* strain.
3. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to claim 2 comprising one or several episomal autonomously replicating DNA elements having a functional *thy A* gene that enables the strain to grow in the absence of thymine in the  
20 growth medium.
4. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to claim 3, wherein the episomal autonomously replicating DNA element is a plasmid.
- 25 5. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to claim 3 or 4 comprising a foreign *thy A* gene.
6. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to claim 5, wherein the foreign *thy A* gene is an *E. coli* gene.
- 30 7. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to any one of claims 3 to 6, wherein the one or several episomal autonomously replicating DNA elements

also comprise a structural gene encoding a homologous or heterologous protein.

8. A  $\Delta$  *thy A* strain of *Vibrio cholerae* according to claim 7, wherein the encoded protein is selected from heat labile enterotoxin B-subunit of *Escherichia coli* (LTB) and *Schistosoma japonicum* glutathione S-transferase 26 kD protein (GST 26 kD).

9. A nucleotide sequence of a structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 1 of FIG. 1.

10. A nucleotide sequence of a 5'-flanking region of a structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 2 of FIG. 2.

11. A nucleotide sequence of a 3'-flanking region of the structural *thy A* gene of *Vibrio cholerae* having essentially the nucleotide sequence SEQ ID NO: 3 of FIG. 3.

12. A protein encoded by a nucleotide sequence of a structural *thy A* gene of *Vibrio cholerae* according to claim 9.

13. A protein according to claim 12, wherein the protein has the amino-acid sequence SEQ ID NO: 4 of FIG. 4.

14. A protein encoded by a nucleotide sequence of a 5'-flanking region of a structural *thy A* gene of *Vibrio cholerae* according to claim 10.

15. A protein according to claim 14, wherein the protein has the amino-acid sequence SEQ ID NO: 5 of FIG. 5.

16. A vaccine comprising as immunising component(s) at least one antigenic component selected from antigenic parts of a *Vibrio cholerae*  $\Delta$  *thy* A strain according to any one of the claims 2 - 8 and a *thy* A<sup>-</sup> strain of *Vibrio cholerae* produced by the method of claim 1.

29305/BN

# ABSTRACT

A method of producing a *thy*<sup>-</sup> strain of *Vibrio cholerae* comprising the step of site-directed mutagenesis in the *V. cholerae* chromosome at the locus of the structural *thy* A gene SEQ ID NO: 1 of FIG. 1, and/or its 5'-flanking region SEQ ID NO: 2 of FIG. 2, and/or its 3'-flanking region SEQ ID NO: 3 of FIG. 3, is described. Particularly, a  $\Delta$  *thy* A strain of *Vibrio cholerae* is disclosed. This strain may comprise one or several episomal autonomously replicating DNA elements, such as plasmids, having an optionally foreign, e.g. *E. coli*, functional *thy* A gene that enables the strain to grow in the absence of thymine in the growth medium, and optionally having a structural gene encoding a homologous or heterologous protein. Further, proteins encoded by the structural gene and the 5'-flanking region are described as SEQ ID NO: 4 of FIG. 4 and SEQ ID NO: 5 of FIG. 5, respectively. Additionally, a vaccine comprising parts of a *Vibrio cholerae*  $\Delta$  *thy* A strain and/or a *thy*<sup>-</sup> strain of *Vibrio cholerae* produced by the method is disclosed.



FIG.1

1/17

SEQ ID NO: 1:

GTGAAACAGT ATTTAGATCT TTGTCAGCGC ATCGTCGATC AAGGTGTTTG GGTGAAAAT	60
GAACGAACGG GCAAGCGTTG TTTGACTGTG ATTAATGCCG ATTTGACCTA CGATGTGGGC	120
AACAATCAGT TTCCTCTAGT GACTACACGC AAGAGTTTTT GGAAAGCTGC CGTAGCCGAG	180
TTGCTCGGCT ATATTCGTGG TTACGATAAT GCGGCGGATT TTCGCCAATT AGGTACCAAA	240
ACCTGGGATG CTAATGCCAA TTTAAACCAA GCATGGCTCA ACAATCCTTA CCGTAAAGGT	300
GAGGATGACA TGGGACGCGT GTATGGTGTT CAGGGTAGAG CTTGGGCTAA GCCTGATGGT	360
GGTCATATTG ACCAGTTGAA AAAGATTGTT GATGATTTGA GCCGTGGCGT TGATGACCGA	420
GGTGAAATTC TTAACCTTCTA CAATCCGGGT GAATTTTACA TGGGGTGTTT GCGCCCTTGC	480
ATGTACAGCC ATCATTTTTTC ATTGCTGGGG GATACCTTGT ATCTCAACAG TACTCAGCGT	540
TCATGTGATG TGCCCTTGGG GTTGAATTTT AACATGGTGC AGGTTTATGT GTTCCTTGCG	600
CTGATGGCAC AGATCACAGG GAAAAAGCCG GGCTTGCGT ATCACAAGAT CGTCAATGCG	660
CACATTTACC AAGATCAACT CGAATTGATG CGCGATGTGC AGCTAAAACG TGAGCCATTC	720
CCAGCGCCTC AGTTCCATAT CAATCCAAAG ATTAAAACAC TGCAGGATTT GGAAACTTGG	780
GTCACCTTGG ATGATTTTGA CGTCACCGGA TATCAGTTCC ACGATCCTAT TCAATACCCG	840
TTTTCAGTC	849

M 02.07.99

FIG.2

2/17

SEQ ID NO: 2:

GAGAAGGTTT	GTTATGCCTC	AGGGTTATCT	GCAGTTTCCC	AATATTGACC	CCGTATTGTT	60
TTCGATCGGC	CCTCTAGCGG	TGCGCTGGTA	TGGCTTGATG	TATTTGGTGG	GTTTCCTTTT	120
TGCTATGTGG	TTGGCCAATC	GCCGAGCGGA	TCGCGCGGGC	AGTGGTTGGA	CGCGTGAGCA	180
AGTCTCTGAC	TTGTTATTCT	CCGGCTTTTT	AGGTGTAGTG	ATCGGTGGCC	GAGTTGGTTA	240
TGTGATCTTC	TACAATTTTG	ATCTGTTTCT	TGCTGACCCT	CTTTATTTAT	TCAAAGTGTG	300
GACTGGCGGC	ATGTCCTTCC	ACGGCGGCTT	ATTGGGTGTG	ATCACCGCCA	TGTTCTGGTA	360
TGCGCGTAAA	AACCAACGCA	CCTTCTTTGG	TGTGGCCGAT	TTTGTTGCCC	CTTTAGTGCC	420
ATTCGGTTTG	GGGATGGGAC	GTATCGGTAA	CTTTATGAAT	AGTGAACTTT	GGGGACGAGT	480
AACGGATGTG	CCTTGGGCTT	TTGTATTCCC	TAATGGTGGC	CCACTGCCGC	GCCATCCTTC	540
ACAGCTTTAT	GAATTCGCCT	TAGAAGGCGT	GGTTCTGTTC	TTTATTCTTA	ATTGGTTTAT	600
TGGTAAACCT	CGTCCGCTAG	GCAGCGTATC	CGGACTGTTT	TTAGCTGGAT	ACGGTACATT	660
CCGCTTCCTT	GTGGAATACG	TCCGTGAGCC	AGATGCTCAG	TTGGGTCTGT	TTGGTGGCTT	720
CATTTCAATG	GGGCAAATCC	TCTCCTTACC	TATGGTGATC	ATCGGTATTT	TGATGATGGT	780
TTGGTCTTAC	AAGCGCGGTT	TGTATCAAGA	CCGTGTAGCA	GCAAAATAGG	GTAGTTAG	838

## FIG.3

3/17

SEQ ID NO: 3:

TAATCCCGTA TTCAGGCGGT ATGGCTTGAT GGGTTTTATA TAAAAAAGC TCCCGAAGGT	60
CGGGAGCTTT TTTTATACAG ATGATGCTTT AACGCTTAAG CGGTTAGGGC AAGAATGCTG	120
CCGGGGATGA CGACAAACAC ACCCAATAAG TAACTCACCA CCACCATTTT GCTCTTACAA	180
GCCCAAGTTG AGATGAGCTC AGCACCTTTA ATAGGCAGTT CGCGTAAGAA AGGAATACCG	240
TAAATCAAGA CCGTAGCCAT CAAGTTAAAG CTTAAGTGCA CCAGCGCAAT TTGCAGAGCA	300
AACACGGCAA ACTCACCAGA GACAGCGGTT GCGGCGAGCA GAGCAGTAAT ACAAGTGCCA	360
ATGTTTCGCAC CTAAGGTAAA TGGGTAGATT TCACGCACTT TCAGCACGCC AGAGCCCACG	420
AGAGGAACCA TTAGGCTGGT TGTGGTCGAT GAAGATTGAA CTAATACCGT AACCCTGTGA	480
CCTGAAGCAA TACCGTGTAG TGGGCCTCGG CCAATCGCAT TTTGTAGAAT TTCACGTGCG	540
CGGCCAACCA TCAAACCTCTT CATCAGTTTG CCCATCACCG TAATGGCGAC GAAAATGGTC	600
GCAATACCCA ATACGATAAG TGCGACACCA CCGAAAGTAT TACCCAATAC CGAAAGCTGG	660
GTTTCAAGCC CTGTGATGAC AGGTTTGGTA ATCGGTTTGA TAAATCAAA ACCTTTCATG	720
CTCATATCGC CAGTCGCAAG CAGAGGCGAA ACGAGCCAGT GTGAGACTTT CTCTAAAATG	780
CCAAACATCA TTTCTAGAGG TAGGAAGATC AGCACCGCGA GAAGATTGAA AAAATCGTGG	840
ATGGTGGCAC TGGCGAAAGC ACGGCGAAAC TCTTCTTTAC AGCGCATATG GCCAAGGCTG	900
ACGAGAGTAT TGGTCACAGT AGTACCAATA TTGGCACCCA TCACCATAGG AATCGCGGTT	960
TCAACCGGTA ACCCACCAGC AACGAGACCA ACAATAATAG AAGTCACCGT GCTTGAGGAT	1020
TGAATCAGTG CCGTTGCCAC TAAACCAATC ATCAATCCTG CAATTGGGTG GGAAGCAAAT	1080
TCAAATAGAA CTTTGGCTTG ATCGCCGGTT GCCCATTTAA AACCGCTGCC GACCATCGCG	1140
ACTGCAAGAA GTAGTAAATA CAGCATGAAA GCCAAGTTTG CCCAACGTAG GCCTTTCGTG	1200
GTCAGCGAAA TCGGCGCTGC AG	1222

11 12 07 99

FIG.4

4/17

SEQ ID NO: 4:

Met	Pro	Gln	Gly	Tyr	Leu	Gln	Phe	Pro	Asn	Ile	Asp	Pro	Val	Leu	Phe	1	5	10	15
Ser	Ile	Gly	Pro	Leu	Ala	Val	Arg	Trp	Tyr	Gly	Leu	Met	Tyr	Leu	Val	20	25	30	
Gly	Phe	Leu	Phe	Ala	Met	Trp	Leu	Ala	Asn	Arg	Arg	Ala	Asp	Arg	Ala	35	40	45	
Gly	Ser	Gly	Trp	Thr	Arg	Glu	Gln	Val	Ser	Asp	Leu	Leu	Phe	Ala	Gly	50	55	60	
Phe	Leu	Gly	Val	Val	Ile	Gly	Gly	Arg	Val	Gly	Tyr	Val	Ile	Phe	Tyr	65	70	75	80
Asn	Phe	Asp	Leu	Phe	Leu	Ala	Asp	Pro	Leu	Tyr	Leu	Phe	Lys	Val	Trp	85	90	95	
Thr	Gly	Gly	Met	Ser	Phe	His	Gly	Gly	Leu	Leu	Gly	Val	Ile	Thr	Ala	100	105	110	
Met	Phe	Trp	Tyr	Ala	Arg	Lys	Asn	Gln	Arg	Thr	Phe	Phe	Gly	Val	Ala	115	120	125	
Asp	Phe	Val	Ala	Pro	Leu	Val	Pro	Phe	Gly	Leu	Gly	Met	Gly	Arg	Ile	130	135	140	
Gly	Asn	Phe	Met	Asn	Ser	Glu	Leu	Trp	Gly	Arg	Val	Thr	Asp	Val	Pro	145	150	155	160
Trp	Ala	Phe	Val	Phe	Pro	Asn	Gly	Gly	Pro	Leu	Pro	Arg	His	Pro	Ser	165	170	175	
Gln	Leu	Tyr	Glu	Phe	Ala	Leu	Glu	Gly	Val	Val	Leu	Phe	Phe	Ile	Leu	180	185	190	
Asn	Trp	Phe	Ile	Gly	Lys	Pro	Arg	Pro	Leu	Gly	Ser	Val	Ser	Gly	Leu	195	200	205	
Phe	Leu	Ala	Gly	Tyr	Gly	Thr	Phe	Arg	Phe	Leu	Val	Glu	Tyr	Val	Arg	210	215	220	
Glu	Pro	Asp	Ala	Gln	Leu	Gly	Leu	Phe	Gly	Gly	Phe	Ile	Ser	Met	Gly	225	230	235	240
Gln	Ile	Leu	Ser	Leu	Pro	Met	Val	Ile	Ile	Gly	Ile	Leu	Met	Met	Val	245	250	255	
Trp	Ser	Tyr	Lys	Arg	Gly	Leu	Tyr	Gln	Asp	Arg	Val	Ala	Ala	Lys	260	265	270		

M 11-07-99

FIG. 5

5/17

SEQ ID NO: 5:

Met	Pro	Gln	Gly	Tyr	Leu	Gln	Phe	Pro	Asn	Ile	Asp	Pro	Val	Leu	Phe	1	5	10	15
Ser	Ile	Gly	Pro	Leu	Ala	Val	Arg	Trp	Tyr	Gly	Leu	Met	Tyr	Leu	Val	20	25	30	
Gly	Phe	Leu	Phe	Ala	Met	Trp	Leu	Ala	Asn	Arg	Arg	Ala	Asp	Arg	Ala	35	40	45	
Gly	Ser	Gly	Trp	Thr	Arg	Glu	Gln	Val	Ser	Asp	Leu	Leu	Phe	Ala	Gly	50	55	60	
Phe	Leu	Gly	Val	Val	Ile	Gly	Gly	Arg	Val	Gly	Tyr	Val	Ile	Phe	Tyr	65	70	75	80
Asn	Phe	Asp	Leu	Phe	Leu	Ala	Asp	Pro	Leu	Tyr	Leu	Phe	Lys	Val	Trp	85	90	95	
Thr	Gly	Gly	Met	Ser	Phe	His	Gly	Gly	Leu	Leu	Gly	Val	Ile	Thr	Ala	100	105	110	
Met	Phe	Trp	Tyr	Ala	Arg	Lys	Asn	Gln	Arg	Thr	Phe	Phe	Gly	Val	Ala	115	120	125	
Asp	Phe	Val	Ala	Pro	Leu	Val	Pro	Phe	Gly	Leu	Gly	Met	Gly	Arg	Ile	130	135	140	
Gly	Asn	Phe	Met	Asn	Ser	Glu	Leu	Trp	Gly	Arg	Val	Thr	Asp	Val	Pro	145	150	155	160
Trp	Ala	Phe	Val	Phe	Pro	Asn	Gly	Gly	Pro	Leu	Pro	Arg	His	Pro	Ser	165	170	175	
Gln	Leu	Tyr	Glu	Phe	Ala	Leu	Glu	Gly	Val	Val	Leu	Phe	Phe	Ile	Leu	180	185	190	
Asn	Trp	Phe	Ile	Gly	Lys	Pro	Arg	Pro	Leu	Gly	Ser	Val	Ser	Gly	Leu	195	200	205	
Phe	Leu	Ala	Gly	Tyr	Gly	Thr	Phe	Arg	Phe	Leu	Val	Glu	Tyr	Val	Arg	210	215	220	
Glu	Pro	Asp	Ala	Gln	Leu	Gly	Leu	Phe	Gly	Gly	Phe	Ile	Ser	Met	Gly	225	230	235	240
Gln	Ile	Leu	Ser	Leu	Pro	Met	Val	Ile	Ile	Gly	Ile	Leu	Met	Met	Val	245	250	255	
Trp	Ser	Tyr	Lys	Arg	Gly	Leu	Tyr	Gln	Asp	Arg	Val	Ala	Ala	Lys		260	265	270	

FIG. 6

6/17






FIG. 8

8/17






FIG. 9

9/17




FIG. 10

10/17




FIG. 11

11/17




FIG. 12

12/17




FIG. 13

13/17




FIG. 14

14/17





FIG. 15

15/17



M 12-07-99

FIG. 16

16/17






FIG. 17

17/17

